Learn how immunotherapies harness a person’s immune system to fight diseases
Learn more about Aduro’s clinical programs
Download the 2018 Annual Report
September 04, 2019 Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?